Global Availability of high-quality pharmaceuticals
We master the complexity of global market entries
Build your portfolio worldwide with us!
We at AET strongly believe that our high-quality medicines should be available throughout the world. Whether living in a developed country or in an emerging market – all patients, irrespective of their origin or nationality, should have access to our affordable medicines making their therapies better and improving their quality of life. That´s why we always strive for a global market entry approach for our customers.
Thanks to our global research and development and regulatory affairs knowledge we have already obtained more than 15.000 marketing authorizations in over 80 markets worldwide. We succeed in mastering the complexity of country-specific regulatory requirements and maintain close contact to the relevant pharmaceutical authorities. In the meantime, our huge network of global marketing partners can focus on their important brand marketing and save time and money.
Our global licensing approach
Global availability of our high-quality pharmaceuticals: marketing authorizations in 80+ countries
How we drive better availability of our high-quality pharmaceuticals throughout the world
Our success factors for your global market entry
We master the complexity of country-specific regulatory requirements to deliver our high-quality pharmaceuticals to as many people as possible
15.000+
MAs obtained
in80+
countries worldwide
150+
marketing partners in five continents
global R&D and regulatory affairs knowledge
15.000+
MAs obtained
in80+
countries worldwide
150+
marketing partners in five continents
global R&D and regulatory affairs knowledge
close contact to pharmaceutical authorities worldwide
highly professional project management
globally oriented supply chain management
several US filings
close contact to pharmaceutical authorities worldwide
highly professional project management
globally orientated supply chain management
several US filings
We are best practice
Mastering the global launch of Rivaroxaban
AET has successfully prepared the complex global registration and launch process of the generic medicine Rivaroxaban, a therapeutically equivalent version of the originator product Xarelto®. Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. Studies have demonstrated the satisfactory quality of our product and its bioequivalence to the reference product. Our country scope covers all relevant Western European and CEE countries, APAC region, Latin America, Middle East as well as Africa. Until today, about 30 states have already granted approval for our product – submissions for over 60 further countries are under preparation or already done.
Rivaroxaban will be manufactured at our own GMP approved, European production site in Cyprus, and (amongst others) marketed by our cooperation partner, one of the biggest generic marketing firms in the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.
Tiefenbacher Pharmaceuticals is driving better global availability of high-quality pharmaceuticals
Pioneering Pharmaceuticals since 1963. We, at TIEFENBACHER PHARMACEUTICALS, provide over 180+ products across various therapeutic categories in 40+ dosage forms. Do not hesitate to get in touch for more information about our global market entry approach. Our experts are always available to help.Please contact us by filling out the contact form below and clicking “Send message”. TIEFENBACHER PHARMACEUTICALS will follow up with you personally as soon as possible.
